Dr. Reardon on the Immunogenicity of Glioblastoma

David A. Reardon, MD
Published: Friday, May 31, 2019



David A. Reardon, MD, clinical director, Center for Neuro-Oncology, institute physician, Dana-Farber Cancer Institute, and professor of medicine, Harvard Medical School, discusses the immunogenicity of glioblastoma.

A phase II study of pembrolizumab (Keytruda) or pembrolizumab plus bevacizumab (Avastin) in recurrent glioblastoma, led by Reardon and colleagues, showed modest activity, leading researchers to believe that glioblastoma is mildly immunogenic. It is now known that certain tumor characteristics, including tumor mutational burden as well as the degree of inherent immune infiltrate, may lend insight into the likelihood of that tumor to respond to immunotherapy, explains Reardon.

This also lends insight into future research efforts, he says. Knowing this, researchers can work to modify an already mildly immunogenic tumor with a limited reserve of T cells. By bringing immune effector T cells into the tumor microenvironment, researchers may be able to manipulate a suppressive environment and bring about a response. It is a complex field to navigate, says Reardon, one that will require additional research efforts.
SELECTED
LANGUAGE


David A. Reardon, MD, clinical director, Center for Neuro-Oncology, institute physician, Dana-Farber Cancer Institute, and professor of medicine, Harvard Medical School, discusses the immunogenicity of glioblastoma.

A phase II study of pembrolizumab (Keytruda) or pembrolizumab plus bevacizumab (Avastin) in recurrent glioblastoma, led by Reardon and colleagues, showed modest activity, leading researchers to believe that glioblastoma is mildly immunogenic. It is now known that certain tumor characteristics, including tumor mutational burden as well as the degree of inherent immune infiltrate, may lend insight into the likelihood of that tumor to respond to immunotherapy, explains Reardon.

This also lends insight into future research efforts, he says. Knowing this, researchers can work to modify an already mildly immunogenic tumor with a limited reserve of T cells. By bringing immune effector T cells into the tumor microenvironment, researchers may be able to manipulate a suppressive environment and bring about a response. It is a complex field to navigate, says Reardon, one that will require additional research efforts.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Overcoming Clinical Inertia in Glioblastoma Multiforme: The Experts Weigh-In on Recent Data Sets and Next Steps to Move the Field ForwardDec 21, 20191.5
Publication Bottom Border
Border Publication
x